Roy_01 schreef op 19 oktober 2019 11:28:
[...]
Je bedoeld hier toch: Ze hebben fase 2 vergeleken met historische data van Baltimore protocol behandelingen (HCST+Immunosupressie)?
Ik vind het wel vreemd deze historische data studie’s zijn vrij recent:
PTCy Literature References: 5. Ciurea SO, et al. Blood 2015; 126: 1033–1040; 8. McCurdy SR, et al. Haematologica 2017; 102:391–400; 10. Devillier R, et al. ASBMT Abstracts 2015; 6:8388–8396; 11. Di Stasi A, et al. Biol Blood Marrow Transplant 2014; 20:1975–1981; 12. Ciurea SO, et al. Biol Blood Marrow Transplant 2012; 18:1835–1844; 13. Solomon SR, et al. Biol Blood Marrow Transplant 2012; 18:1859–1866; 14. Esquirol A, et al. Bone Marrow Transplant 2016; 51:S314–S513; 15. Piemontese S, et al. J Hematol Oncol 2017; 10:24; 16. Sugita J, et al. Biol Blood Marrow Transplant 2015; 21:1646–1652; 17. Kanate AS, et al. Blood 2016; 127:938–947; 18. Bashey A, et al. Biol Blood Marrow Transplant 2016; 22:125–133; 19. Slade M, et al. Biol Blood Marrow Transplant 2017; 23:1736– 1743; 20. Kasamon YL, et al. Blood Adv 2017; 1:288–292; 21. Fraccaroli A, et al. Am J Hematol 2018; Epub ahead of print; 22. Baker M, et al. Biol Blood Marrow Transplant 2016; 22:2047–2055; 23. Carnevale-Schianca F, et al. Biol Blood Marrow Transplant 2017; 23:459–466; 24. Kwon M, et al. Bone Marrow Transplant 2017; 52:1138–1143; 25. Ruggeri A, et al. Haematologica 2017; 102:401– 410; 26. Srour SA, et al. Biol Blood Marrow Transplant 2017; 23:318–324; 27. Devillier R, et al. Bone Marrow Transplant 2016; 51:194–198; 28. Duléry R, et al. Biol Blood Marrow Transplant 2018; 24:1013–1021; 29. Gaballa S, et al. Cancer 2016; 122:3316–3326; 30. Lorentino F, et al. Blood Adv 2017; 1:669–680; 31. Rashidi A, et al. Bone Marrow Transplant 2016; 51:1561–1564; 32. Robin M, et al. Biol Blood Marrow Transplant 2018; Epub ahead of print; 33. Robin M, et al. Blood Adv 2017; 1:1876–1883; 34. Santoro N, et al. J Hematol Oncol 2017; 10:113; 35. Rovers J, et al. EBMT 2017; poster presentation #A171; 36. Clinicaltrials.gov.
Als je dan met name de gemiddelde chronische GVHD bekijkt op dat clinical fact sheet: (22% PTCy 3% Atir101).
Dan kan ik mij moeilijk voorstellen dat men ineens 86% minder cGVHD heeft met PTCy.
En relapse 25% t.o.v. 8%, 68% vermindering.
www.kiadis.com/wp-content/uploads/201...